arrow
J

Jing Yi Lee

national cancer centre singapore
H指数:11
被引数:302

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Distinct subtypes of kidney transplant-associated urothelial carcinomas harboring BK polyomavirus integration and aristolochic acid mutational signatures

BK多瘤病毒整合和马兜铃酸突变特征所具有的肾移植相关尿路上皮癌的不同亚型

2026-05-230
OAAI
Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers

揭示BAP1去泛素化景观,增强了BAP1缺陷型泛癌机制的阐明和治疗的精准性

2026-04-010
PRE
Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma

Brincidofovir在周围T细胞和NK/T细胞淋巴瘤中的临床前活性

2026-02-060
OAAI
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population

在多样化亚洲人群中,一种泛癌种基于组织的联合DNA和RNA下一代测序检测具有高度临床可操作性。

2025-11-130
OAAI
Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma- Potential Synergy with Immune Checkpoint Blockade

非霍奇金淋巴瘤中布马那韦的治疗重定位——与免疫检查点阻断的潜在协同作用

BLOOD
IF23.1
2024-11-050
PRE
Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade

马兜铃酸相关肾细胞癌表现出独特的肿瘤免疫微环境,有利于对免疫检查点阻断的反应

2024-10-030
OA
Comprehensive molecular characterization of collecting duct carcinoma for therapeutic vulnerability

集合管癌治疗易损性的综合分子表征

2024-08-090
PRE
Integrative Multi-Omics Enhancer Activity Profiling Identifies Therapeutic Vulnerabilities in Cholangiocarcinoma of Different Etiologies
2024-04-150
PRE
Potent anti-proliferative activity of brincidofovir in Diffuse Large B-cell Lymphoma with overexpression of transcriptional repressor TLE1
2024-03-220
PRE
Real-world experience of an Asian pan-cancer combined DNA/RNA next generation sequencing (NGS) tissue biopsy assay
2024-03-220
PRE